PMC:7536954 / 2474-2676 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T4","span":{"begin":75,"end":86},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma45303"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T3","span":{"begin":80,"end":86},"obj":"Body_part"}],"attributes":[{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0009472"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T38","span":{"begin":113,"end":115},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"mondo_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/MONDO_0006559"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T18","span":{"begin":80,"end":86},"obj":"http://www.ebi.ac.uk/efo/EFO_0001395"},{"id":"T19","span":{"begin":167,"end":168},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T20","span":{"begin":199,"end":200},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T26","span":{"begin":113,"end":115},"obj":"Chemical"}],"attributes":[{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_74056"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"92","span":{"begin":32,"end":43},"obj":"Chemical"},{"id":"93","span":{"begin":146,"end":157},"obj":"Chemical"}],"attributes":[{"id":"A92","pred":"tao:has_database_id","subj":"92","obj":"MESH:C555450"},{"id":"A93","pred":"tao:has_database_id","subj":"93","obj":"MESH:C555450"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T24","span":{"begin":113,"end":115},"obj":"Phenotype"}],"attributes":[{"id":"A24","pred":"hp_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/HP_0040154"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T22","span":{"begin":0,"end":52},"obj":"Sentence"},{"id":"T23","span":{"begin":53,"end":202},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Figure 1 Clinical response to secukinumab therapy. Manifestations at the left axilla consisted of inflammatory HS nodules and fistulas prior to secukinumab therapy (a) and after 20‐week treatment (b)."}